In the sedentary era, weight gain is becoming a serious preventable risk factor for increased body mass index which strongly correlates with enhanced cancer threat.
As reported cancers of endometrial, oesophageal adenocarcinoma, colorectal, postmenopausal breast, prostate & renal are caused due to surplus weight. The mechanism behind obesity and cancer partnership. The body’s lean shape is regulated by the delicate balance between adipocytes & immune cells. Chronic nutrient overload leads to adipocyte hypertrophy, mitochondrial dysfunction, increased oxidative & endoplasmic reticulum stress, proinflammatory signalling, adipokine secretion & cell death. Collectively instigate enhanced secretion of proinflammatory factors, dysregulated systemic metabolism, tumour growth, metastasis & progression.
• Alteration in an adipose stromovascular fraction
• Reduction in anti-inflammatory Treg & TH2 cells
• Increase in proinflammatory TH1 & CD8+T cells
• Variation in M2 to M1 macrophages
1. Adipokines - Weight gain alters the interaction between adipocytes, adipokine production
2. Adiponectin- Obesity triggers adiponectin reduction & causes a mutation in adiponectin receptors (ADIPOR1 & ADIPR2)
3. Leptin -Excessive weight facilitates leptin resistance & hyperlipidaemia, enables cell proliferation, migration, invasion responses, and tumour development
4. Estrogen- Increased weight fosters adipose-derived aromatase activity, estrogen production, systemic estrogen bioavailability, adipose-derived proinflammatory factors (IL-1β, IL-6, prostaglandin E2, and TNFα), liver-derived insulin growth factor 1 (IGF-1)
5. IL-6 and TNFα- Obesity-induced excess IL-6 and TNFα levels encourage cellular transformation, proliferation, invasion, angiogenesis, metastasis, cancer cell proliferation, survival & angiogenesis.
6. IL-1β- Heavy weight increases free fatty acid, cholesterol, blood sugar, and free radical’s levels stimulating tumour expression of IL-1β, NOD-like receptor family, pyrin domain containing 3 (NLRP3) & inflammasome activity
7. Osteopenia-Neoplastic transformation, cancer cell survival & metastasis progression enhances due to obesity-driven osteopenia phosphoprotein
8. YKL-40- Excessive obesity with diabetes generate YKL-40, cancer cell proliferation, angiogenesis, and extracellular matrix remodelling
9. PAI-1- Advancing obesity increases PAI-1 (serine protease inhibitor), cancer cell invasion, metastasis & tumours
10. Endotrophic -Increased adipose tissue promotes endotrophic production, activates TGF-β signalling, tumour cell growth & metastasis
• Central obesity causes insulin resistance, dyslipidaemia, hyperglycaemia & metabolic dysfunction
• Visceral adipose tissue aggravates the abdominal cavity’s momentum & produces more proinflammatory factors
Weight loss decreases infiltrating macrophages in adipose tissue inflammation, systemic complications of proinflammatory adipokines, obesity-linked pathologies & delays carcinogenesis. Dietary restriction-motivated weight loss reduces colorectal inflammation, decreases rectosigmoid expression of multiple proinflammatory cytokines and markers of T -cell, macrophage accumulation & attenuates cancer
pathways (FOS, JUN, STAT3, and NF-κB expression).
Visible weight loss reduces cancer risk, diminishes adipose-related inflammatory mechanisms, regulates tumour development & progression. Reduction and control of cancer risk demand a better understanding of cellular & molecular mechanisms behind obesity-induced inflammation, the proactive invention of early diagnosis biomarkers & accessible effective cancer therapy.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Belgian Algorithm Reshapes Endometrial Cancer Care
2.
ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer
3.
Nuclear missile workers are contracting cancer: They blame the bases
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology
1.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
2.
Consensus Recommendations for Healthy Hematologic Aging
3.
The Role of Alanine Aminotransferase in Liver Health and Disease
4.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
5.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation